Paysign, Inc. Reports Strong Q3 2024 Financial Performance

Revenue Growth
Paysign, Inc. (PAYS) announced a year-over-year revenue increase during its third-quarter earnings call, showcasing strength mainly in its patient affordability business. CEO Mark Newcomer highlighted a 23% revenue growth to $15.3 million and a 20.6% increase in adjusted EBITDA to $2.8 million. The company plans to expand offerings and has established a partnership with a leading pharmaceutical company. Despite challenges in the plasma sector, Paysign has a positive outlook, forecasting revenue of $56.5 million to $58.5 million and net income between $3 million and $3.5 million for the year.

Key Takeaways

• Revenue rose 23% YoY to $15.3 million in Q3.
• Adjusted EBITDA grew 20.6% to $2.8 million.
• Patient affordability segment surged 219% with 66 active programs.
• Plasma donor compensation revenue increased 3.4% to $11.4 million.
• Gross margins improved to 55.5%.
• Full-year revenue expected between $56.5 million and $58.5 million.
• Remaining budget for share repurchase program stands at $3.5 million.

Company Outlook

• Paysign anticipates revenue growth of 20% to 24% YoY.
• Projected gross profit margins between 54% and 55%.
• Operating expenses expected between $30 million and $32 million.
• Full-year net income forecasted at $3 million to $3.5 million.

Risks and Opportunities

Bearish Highlights

• Plasma business affected by external factors.
• Ongoing legal expenses nearing $600,000.

Bullish Highlights

• Continued strong growth in the pharma segment.
• Total addressable market for patient affordability exceeds $500 million.
• Competitive edge through focus on patient affordability.

Misses

• Lacks patented technology but has unique proprietary advantages.

Q&A Highlights

• Strategy allows for rapid onboarding of claims, with potential immediate increases.
• Competitive advantage lies in unique technology and pricing strategies.

In Q3 2024, Paysign demonstrated strong financial growth, particularly in patient affordability. While facing plasma business challenges, its optimistic outlook suggests continued upward momentum in performance and operational strength.

InvestingPro Insights

Paysign's Q3 2024 performance aligns with a 27.75% revenue surge over the last twelve months. The revenue increase accompanies a relatively small market cap of $214.94 million, reflecting strong market interest. However, a significant stock price drop over the previous three months may present investment opportunities.

Full Transcript – Paysign Inc (PAYS) Q3 2024

Operator: Good afternoon…

Mark Newcomer: …We announced our financial results…

Jeff Baker: …Plasma donor compensation revenue…

Mark Newcomer: Thank you all for joining today’s call. Your continued support …

This article was generated with AI support and reviewed by an editor. Please see our T&C for more details.